A 7.0–7.7% value for glycated haemoglobin is better than a <7% value as an appropriate target for patient-centered drug treatment of type 2 diabetes mellitus

Diabetes mellitus is an increasingly important condition, the vast majority of cases being of the type 2 variety. More than four hundred million people lived with diabetes mellitus in the world in 2014, according to the World Health Organization (1). Diabetes mellitus is frequently associated with cardio-vascular disease, and the simultaneous presence of both conditions is associated with a significant mortality risk (2).